Tenofovir alafenamide for treating chronic hepatitis B
Based on two ongoing studies comparing the efficacy and safety of tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) for the treatment of chronic hepatitis B patients, this study on “96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection” confirms previous results obtained from 48-week figures and shows that TAF continues to be as effective as TDF with significantly less bone and renal toxicity even after two years of treatment (J Hepatol (2018), https://doi.org/ 10.1016/j.jhep.2017.11.039).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Henry Chan, Head of Division of Gastroenterology and Hepatology in our Department of Medicine and Therapeutics. Prof Chan is an expert in antiviral treatment of chronic hepatitis and has led numerous global clinical trials in the development of antiviral therapies.
Full article: http://www.sciencedirect.com/science/article/pii/S0168827817324911